Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).
about
Better control of early viral replication is associated with slower rate of elicited antiviral antibodies in the detuned enzyme immunoassay during primary HIV-1C infection.Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses.Binding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children.Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).Cell-associated HIV RNA: a dynamic biomarker of viral persistence.Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy.The effect of viral suppression on cross-sectional incidence testing in the johns hopkins hospital emergency department.Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope.Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy.Anti-human immunodeficiency virus type 1 humoral immune response and highly active antiretroviral treatment.Mother to child transmission of HIV-1 in a Thai population: role of virus characteristics and maternal humoral immune response.
P2860
Q33625545-FD595F9E-8372-4945-ABE0-024B38D46D0DQ34651668-06BD527B-F230-44BA-9B6A-A109CA4925ACQ35604169-C10F5996-1ADB-477F-AC9A-22DF818A8631Q36421569-558B6ED2-A155-4095-B48E-EECB2E7B596BQ36798408-EDC8D420-1CF3-47EA-A68F-B46F5719E2C8Q37072991-0FD860E8-D352-4D53-A366-27601D6DD4EAQ37335555-AF10B189-7105-438D-A602-81256E32C2B7Q37646897-6BCE11D6-3F1E-48CA-BF54-4DB6BB703D43Q40145762-3D6B1CA9-3F06-408C-8BF7-3F058ADA7FACQ40440245-27D2AFFF-6A35-4860-AEB9-754D8D55316EQ42196466-CB657BBB-C2D1-4311-8DDF-CCF45C8068EEQ43750850-5F52F057-5335-4759-AD02-4777C701CD3FQ45385737-F2D0F694-523C-47C6-9B8D-96F0942B77CE
P2860
Characterization of the HIV-1 specific humoral immune response during highly active antiretroviral therapy (HAART).
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Characterization of the HIV-1 ...... ntiretroviral therapy (HAART).
@en
Characterization of the HIV-1 ...... active antiretroviral therapy
@nl
type
label
Characterization of the HIV-1 ...... ntiretroviral therapy (HAART).
@en
Characterization of the HIV-1 ...... active antiretroviral therapy
@nl
prefLabel
Characterization of the HIV-1 ...... ntiretroviral therapy (HAART).
@en
Characterization of the HIV-1 ...... active antiretroviral therapy
@nl
P2093
P1476
Characterization of the HIV-1 ...... ntiretroviral therapy (HAART).
@en
P2093
Israelski D
Katzenstein DA
P304
P356
10.1097/00042560-200112150-00001
P407
P577
2001-12-01T00:00:00Z